Use the search to find what you are looking for
Disappointingly, the findings of the long-running GEFPCAPI trial led by Dr Fizazi of the Institut Gustave Roussy have proved negative. The trial has concluded that:
“In GEFCAPI 04, using a molecular test followed by tailored systemic treatment did not improve outcomes of patients with carcinomas of the unknown primary site.”
The trial ran from March 2012 to February 2018 in 4 EU countries. 21 patients received the Tissue of Origin test, and 222 received the CancerTYPE ID test.
The relevant paper is:
2019. A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of unknown primary (CUP) site (GEPCAPI 04). Fizazi K, Maillard A, Penel A, et al. Ann Oncol 2019;30:5S. Presented at ESMO Sep 2019